Income Statement (TTM)
Aion Therapeutic Inc. Income Statement shows changes in income and expenses over a period of time. Income Statement data includes Sales and Revenue, Gross Profit, Research and Development (R&D), Selling, General and Administrative Expense (SG&A), Operating Income, Income Tax Expense, Interest Expense, Non-Operating Income, Earnings per Share (EPS), and Shares Outstanding.
All numbers are times 1,000,000 except per share units.
|
2024 01-31 |
2024 04-30 |
2024 07-31 |
2024 10-31 |
2025 01-31 |
|
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 1 | 1 | 1 |
| Change (%) | 65.50 | 118.34 | 43.33 | 28.08 | |
| % of Revenue | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 |
| Cost Of Sales | 0 | 0 | 0 | 1 | 1 |
| Change (%) | 250.40 | 118.15 | 53.84 | 45.42 | |
| % of Revenue | 26.27 | 55.61 | 55.56 | 59.64 | 67.71 |
| Gross Operating Profit | 0 | 0 | 0 | 0 | 0 |
| Change (%) | -0.37 | 118.58 | 30.18 | 2.47 | |
| % of Revenue | 73.73 | 44.39 | 44.44 | 40.36 | 32.29 |
| SG&A | 1 | 1 | 2 | 2 | 2 |
| Change (%) | 29.03 | 24.04 | 20.41 | -0.33 | |
| % of Revenue | 440.27 | 343.25 | 195.01 | 163.83 | 127.49 |
| R&D | |||||
| Change (%) | |||||
| % of Revenue | |||||
| OpEx | 1 | 2 | 2 | 3 | 3 |
| Change (%) | 43.47 | 38.03 | 28.25 | 12.29 | |
| % of Revenue | 473.34 | 410.32 | 259.40 | 232.11 | 203.49 |
| Operating Income | -1 | -1 | -1 | -2 | -2 |
| Change (%) | 37.57 | 12.15 | 18.79 | 0.34 | |
| % of Revenue | -373.34 | -310.32 | -159.40 | -132.11 | -103.49 |
| Interest Expense | -0 | -0 | -0 | -0 | -0 |
| Change (%) | 13.75 | 12.66 | 13.05 | 51.71 | |
| % of Revenue | -67.86 | -46.64 | -24.07 | -18.98 | -22.48 |
| Net Income | -1 | -6 | -6 | -7 | -7 |
| Change (%) | 473.35 | 0.67 | 6.34 | -1.27 | |
| % of Revenue | -493.85 | -1,710.90 | -788.87 | -585.31 | -451.18 |
Source: Capital IQ
